Vertex Pharmaceuticals (VRTX) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Vertex Pharmaceuticals (NASDAQ: VRTX):

• 3/25/2026 – Vertex Pharmaceuticals was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/18/2026 – Vertex Pharmaceuticals was upgraded by Maxim Group from “hold” to “buy”. They now have a $575.00 price target on the stock.
• 3/11/2026 – Vertex Pharmaceuticals had its price target raised by Truist Financial Corporation from $490.00 to $525.00. They now have a “buy” rating on the stock.
• 3/10/2026 – Vertex Pharmaceuticals had its price target raised by Morgan Stanley from $570.00 to $596.00. They now have an “overweight” rating on the stock.
• 3/10/2026 – Vertex Pharmaceuticals had its price target raised by Bank of America Corporation from $571.00 to $598.00. They now have a “buy” rating on the stock.
• 3/10/2026 – Vertex Pharmaceuticals had its price target raised by Citigroup Inc. from $575.00 to $585.00. They now have a “buy” rating on the stock.
• 3/10/2026 – Vertex Pharmaceuticals is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $580.00 price target on the stock.
• 3/10/2026 – Vertex Pharmaceuticals had its price target raised by Oppenheimer Holdings, Inc. from $540.00 to $600.00. They now have an “outperform” rating on the stock.
• 3/10/2026 – Vertex Pharmaceuticals had its price target raised by HC Wainwright from $591.00 to $641.00. They now have a “buy” rating on the stock.
• 2/17/2026 – Vertex Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $411.00 to $441.00. They now have a “hold” rating on the stock.
• 2/17/2026 – Vertex Pharmaceuticals had its price target raised by Barclays PLC from $606.00 to $607.00. They now have an “overweight” rating on the stock.
• 2/17/2026 – Vertex Pharmaceuticals was given a new $591.00 price target by HC Wainwright.
• 2/13/2026 – Vertex Pharmaceuticals had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $570.00 price target on the stock.
• 2/13/2026 – Vertex Pharmaceuticals had its price target raised by Scotiabank from $495.00 to $558.00. They now have an “outperform” rating on the stock.
• 2/13/2026 – Vertex Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $546.00 to $541.00. They now have an “outperform” rating on the stock.
• 2/13/2026 – Vertex Pharmaceuticals had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $577.00 price target on the stock.
• 2/13/2026 – Vertex Pharmaceuticals had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $590.00 price target on the stock.
• 2/13/2026 – Vertex Pharmaceuticals had its price target raised by Stifel Nicolaus from $445.00 to $466.00. They now have a “hold” rating on the stock.
• 2/13/2026 – Vertex Pharmaceuticals had its price target raised by HC Wainwright from $478.00 to $518.00. They now have a “buy” rating on the stock.
• 2/13/2026 – Vertex Pharmaceuticals was upgraded by Oppenheimer Holdings, Inc. from “market perform” to “outperform”. They now have a $540.00 price target on the stock.
• 2/4/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 1/27/2026 – Vertex Pharmaceuticals was upgraded by Barclays PLC from “equal weight” to “overweight”. They now have a $606.00 price target on the stock, up from $414.00.
• 1/26/2026 – Vertex Pharmaceuticals had its price target raised by UBS Group AG from $535.00 to $545.00. They now have a “buy” rating on the stock.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP Duncan Mckechnie sold 4,910 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total transaction of $2,394,361.50. Following the completion of the transaction, the executive vice president directly owned 17,559 shares in the company, valued at approximately $8,562,646.35. This represents a 21.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Amit Sachdev sold 1,846 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $897,802.10. Following the sale, the executive vice president directly owned 55,570 shares of the company’s stock, valued at $27,026,469.50. The trade was a 3.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 93,485 shares of company stock valued at $43,967,586 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.